Minciuna Iulia, van Kleef Laurens A, Stefanescu Horia, Procopet Bogdan
Regional Institute of Gastroenterology and Hepatology Octavian Fodor, 400394 Cluj-Napoca, Romania.
3rd Medical Department, University of Medicine and Pharmacy Iuliu Hatieganu, 400347 Cluj-Napoca, Romania.
Cancers (Basel). 2022 Oct 17;14(20):5084. doi: 10.3390/cancers14205084.
Hepatocellular carcinoma (HCC), one of the leading causes of cancer-related deaths worldwide, is a multistep process that usually develops in the background of cirrhosis, but also in a non-cirrhotic state in patients with non-alcoholic fatty liver disease (NAFLD) or viral hepatis. Emerging evidence suggests that intermittent fasting can reduce the risk of cancer development and could improve response and tolerance to treatment through the metabolic and hormonal adaptations induced by the low energy availability that finally impairs cancer cells' adaptability, survival and growth. The current review will outline the beneficial effects of fasting in NAFLD/NASH patients and the possible mechanisms that can prevent HCC development, including circadian clock re-synchronization, with a special focus on the possibility of applying this dietary intervention to cirrhotic patients.
肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一,是一个多步骤过程,通常在肝硬化背景下发生,但也可在非酒精性脂肪性肝病(NAFLD)或病毒性肝炎患者的非肝硬化状态下发生。新出现的证据表明,间歇性禁食可以降低癌症发生风险,并通过低能量供应引起的代谢和激素适应来改善对治疗的反应和耐受性,最终损害癌细胞的适应性、生存和生长。本综述将概述禁食对NAFLD/NASH患者的有益影响以及可能预防HCC发生的机制,包括昼夜节律重新同步,特别关注将这种饮食干预应用于肝硬化患者的可能性。